proxyvotesnow.com
23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ATARA BIOTHERAPEUTICS INC. › 2023-2024

ATARA BIOTHERAPEUTICS INC. 2023-2024 Proxy Voting Records

At ATARA BIOTHERAPEUTICS INC.'s shareholder meeting held June 10, 2024, in the 2023-2024 proxy season, 97 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,000 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — ATARA BIOTHERAPEUTICS INC.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ATARA BIOTHERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2024.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ATARA BIOTHERAPEUTICS INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 9Reported items
  • 97Asset managers
  • 1,000Fund votes
  • June 10, 2024Meeting date

Results at a glance

Meeting of June 10, 2024: 9 items on ATARA BIOTHERAPEUTICS INC.’s Form 8-K, filed June 11, 2024: 2 elected · 6 approved · 1 not approved.

Not approved or not elected

  • 5. Approval of automatic annual increase to the Company's 2024 Equity Incentive Plan 38% of votes cast Not approved Under 80%

Material dissent

  • 4. Approval of the Company's 2024 Equity Incentive Plan 76% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024

Explore ATARA BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ATARA BIOTHERAPEUTICS INC.

These tallies are ATARA BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ATARA BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held June 10, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: William K. Heiden 64,365,411---- 6,765,96124,841,883 90%Elected—
Elect Director: Ameet Mallik 58,254,661---- 12,876,71124,841,883 82%Elected—
2. Advisory vote to approve on the compensation of the Company's named executive officers 63,970,4876,810,564350,321 --24,841,883 90%Approved—
3. Ratification of appointment of independent registered public accounting firm 89,685,0786,077,689210,488 ---- 94%Approved—
4. Approval of the Company's 2024 Equity Incentive Plan 53,961,76816,999,707169,897 --24,841,883 76%Approved—
5. Approval of automatic annual increase to the Company's 2024 Equity Incentive Plan 26,632,38544,285,524213,463 --24,841,883 38%Not approved—
6. Approval of increase in number of common stock available for issuance under Company's 2014 Employee Stock Purchase Plan 64,172,3196,917,34841,705 --24,841,883 90%Approved—
7. Approval of amendment to Company's Certificate of Incorporation to effect a reverse stock split 85,657,5549,877,294438,407 ---- 90%Approved—
8. Approval of adjournment of the annual meeting for further solicitation 80,507,78014,437,9981,027,477 ---- 85%Approved—

Source: ATARA BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.

How asset managers voted at the ATARA BIOTHERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 97 asset managers that disclosed a ATARA BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ATARA BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Ameet Mallik

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 58,254,661WITHHELD: 12,876,711
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: Election of Directors: Ameet Mallik

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Ameet Mallik”): 58,254,661 for, 12,876,711 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the two nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their respective successors are elected.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 15,661,682 for, 523,455 withheld.

FOR
FOR: 15,661,682WITHHOLD: 523,455
Largest asset managers voting on “Election of Directors: Ameet Mallik” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable233,7630 0167,200Mixed
John Hancock155,8000 023,063Mixed
Lincoln Financial169,9910 00For
Voya00 0146,063Withhold
AIG/SunAmerica00 047,731Withhold
Brighthouse00 038,063Withhold
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide7,2190 024,381Mixed
Principal Exchange-Traded Funds00 029,062Withhold
SEI20,6000 00For
State Street20,1070 00For
ProShares00 015,724Withhold
DWS00 013,001Withhold
Principal00 09,726Withhold
Calvert00 06,782Withhold
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC2,9280 00For
Guggenheim00 02,372Withhold

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

2. Elect Director: William K. Heiden

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 64,365,411WITHHELD: 6,765,961
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: Election of Directors: William K. Heiden

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: William K. Heiden”): 64,365,411 for, 6,765,961 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the two nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their respective successors are elected.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 16,017,650 for, 167,487 withheld.

FOR
FOR: 16,017,650WITHHOLD: 167,487
Largest asset managers voting on “Election of Directors: William K. Heiden” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable233,7630 0167,200Mixed
John Hancock178,8630 00For
Lincoln Financial169,9910 00For
Voya146,0630 00For
AIG/SunAmerica47,7310 00For
Brighthouse38,0630 00For
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide31,6000 00For
Principal Exchange-Traded Funds29,0620 00For
SEI20,6000 00For
State Street20,1070 00For
ProShares15,7240 00For
DWS13,0010 00For
Principal9,7260 00For
Calvert6,7820 00For
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC2,9280 00For
Guggenheim2,3720 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

3. Approval of amendment to Company's Certificate of Incorporation to effect a reverse stock split

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 85,657,554AGAINST: 9,877,294
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: To approve an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-4 and 1-for-30, as determined by the Board of Directors in its discretion, subject to the Board of Directors' authority to abandon such amendments (the "Charter Amendment Proposal").

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“7. Approval of amendment to Company's Certificate of Incorporation to effect a reverse stock split”): 85,657,554 for, 9,877,294 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-4 and 1-for-30, as determined by the Company's Board of Directors in its dis…”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 16,185,137 for.

FOR
FOR: 16,185,137
Largest asset managers voting on “To approve an amendment to the Company's amended and restated certificate of incorporation to effect a reverse” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable400,9630 00For
John Hancock178,8630 00For
Lincoln Financial169,9910 00For
Voya146,0630 00For
AIG/SunAmerica47,7310 00For
Brighthouse38,0630 00For
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide31,6000 00For
Principal Exchange-Traded Funds29,0620 00For
SEI20,6000 00For
State Street20,1070 00For
ProShares15,7240 00For
DWS13,0010 00For
Principal9,7260 00For
Calvert6,7820 00For
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC2,9280 00For
Guggenheim2,3720 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

4. Approval of adjournment of the annual meeting for further solicitation

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

85% Approved · of votes cast

FOR 85%AGAINST
FOR: 80,507,780AGAINST: 14,437,998
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOLICITATION AND VOTE OF PROXIES IN THE EVENT THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE CHARTER AMENDMENT PROPOSAL.

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“8. Approval of adjournment of the annual meeting for further solicitation”): 80,507,780 for, 14,437,998 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 8: Approval of adjournment of the annual meeting for further solicitation”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 11,766,940 for, 4,418,197 against.

FORAGAINST
FOR: 11,766,940AGAINST: 4,418,197
Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOL” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price04,108,759 00Against
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable352,36348,600 00Mixed
John Hancock23,063155,800 00Mixed
Lincoln Financial89,69180,300 00Mixed
Voya146,0630 00For
AIG/SunAmerica47,7310 00For
Brighthouse38,0630 00For
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide31,6000 00For
Principal Exchange-Traded Funds29,0620 00For
SEI20,6000 00For
State Street020,107 00Against
ProShares15,7240 00For
DWS13,0010 00For
Principal9,7260 00For
Calvert6,7820 00For
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC02,928 00Against
Guggenheim2,3720 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

5. To approve an automatic annual increase to the company's 2024 equity incentive plan.

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

7% of fund votes cast · no official result

AGAINST
Details: description as filed, votes by 29 asset managers

Description as filed by funds: TO APPROVE AN AUTOMATIC ANNUAL INCREASE TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN.

The 29 asset managers below reported 1,055,691 for, 15,129,446 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 1,055,691AGAINST: 15,129,446
Largest asset managers voting on “TO APPROVE AN AUTOMATIC ANNUAL INCREASE TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN.” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard04,311,772 00Against
T. Rowe Price04,108,759 00Against
BlackRock02,876,886 00Against
Fidelity01,947,100 00Against
JPMorgan966,0000 00For
Charles Schwab0762,050 00Against
Equitable0400,963 00Against
John Hancock0178,863 00Against
Lincoln Financial89,69180,300 00Mixed
Voya0146,063 00Against
AIG/SunAmerica047,731 00Against
Brighthouse038,063 00Against
Bridge Builder Trust037,583 00Against
Pacific Life036,126 00Against
Nationwide031,600 00Against
Principal Exchange-Traded Funds029,062 00Against
SEI020,600 00Against
State Street020,107 00Against
ProShares015,724 00Against
DWS013,001 00Against
Principal09,726 00Against
Calvert06,782 00Against
Morgan Stanley03,264 00Against
PENN SERIES FUNDS INC02,928 00Against
Guggenheim02,372 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

6. Approval of increase in number of common stock available for issuance under Company's 2014 Employee Stock Purchase Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 64,172,319AGAINST: 6,917,348
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: TO APPROVE AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER THE COMPANY'S 2014 EMPLOYEE STOCK PURCHASE PLAN.

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“6. Approval of increase in number of common stock available for issuance under Company's 2014 Employee Stock Purchase Plan”): 64,172,319 for, 6,917,348 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the increase in the number of shares of common stock available for issuance under the Company's 2014 Employee Stock Purchase Plan.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 16,185,137 for.

FOR
FOR: 16,185,137
Largest asset managers voting on “TO APPROVE AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER THE COMPANY'S 2014” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable400,9630 00For
John Hancock178,8630 00For
Lincoln Financial169,9910 00For
Voya146,0630 00For
AIG/SunAmerica47,7310 00For
Brighthouse38,0630 00For
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide31,6000 00For
Principal Exchange-Traded Funds29,0620 00For
SEI20,6000 00For
State Street20,1070 00For
ProShares15,7240 00For
DWS13,0010 00For
Principal9,7260 00For
Calvert6,7820 00For
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC2,9280 00For
Guggenheim2,3720 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

7. To approve the company's 2024 equity incentive plan.

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

87% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: TO APPROVE THE COMPANY'S 2024 EQUITY INCENTIVE PLAN.

The 29 asset managers below reported 14,140,757 for, 2,044,380 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 14,140,757AGAINST: 2,044,380
Largest asset managers voting on “TO APPROVE THE COMPANY'S 2024 EQUITY INCENTIVE PLAN.” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,586,617360,483 00Mixed
JPMorgan0966,000 00Against
Charles Schwab762,0500 00For
Equitable233,763167,200 00Mixed
John Hancock155,80023,063 00Mixed
Lincoln Financial0169,991 00Against
Voya0146,063 00Against
AIG/SunAmerica047,731 00Against
Brighthouse038,063 00Against
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide7,21924,381 00Mixed
Principal Exchange-Traded Funds029,062 00Against
SEI20,6000 00For
State Street020,107 00Against
ProShares015,724 00Against
DWS013,001 00Against
Principal09,726 00Against
Calvert06,782 00Against
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC02,928 00Against
Guggenheim02,372 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

8. Advisory vote to approve on the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 63,970,487AGAINST: 6,810,564
Details: description as filed, official tally, votes by 97 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“2. Advisory vote to approve on the compensation of the Company's named executive officers”): 63,970,487 for, 6,810,564 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 29 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable400,9630 00For
John Hancock178,8630 00For
Lincoln Financial169,9910 00For
Voya146,0630 00For
AIG/SunAmerica47,7310 00For
Brighthouse38,0630 00For
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide31,6000 00For
Principal Exchange-Traded Funds29,0620 00For
SEI20,6000 00For
State Street20,1070 00For
ProShares15,7240 00For
DWS13,0010 00For
Principal9,7260 00For
Calvert06,782 00Against
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC2,9280 00For
Guggenheim2,3720 00For

Fund voting reports, all 29 managers: 16,178,355 for, 6,782 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 78 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
EcoR1 Capital, LLC010,167,043 00Against
Redmile Group, LLC9,263,3090 00For
T. Rowe Price4,928,4400 00For
Citadel4,643,3070 00For
Boxer Capital, LLC4,150,0000 00For
BlackRock2,606,2960 00For
Vestal Point Capital, LP2,371,7560 00For
Woodline Partners LP2,169,8770 00For
State Street2,010,219157 00For
GEODE CAPITAL MANAGEMENT, LLC1,717,3170 00For
AQR1,321,9460 00For
JPMorgan1,149,7370 00For
J. Goldman & Co LP1,087,6350 00For
ACADIAN ASSET MANAGEMENT LLC1,075,3140 00For
STALEY CAPITAL ADVISERS INC1,000,0000 00For
Charles Schwab762,0500 00For
MELLON INVESTMENTS Corp579,6830 00For
Northern Trust493,6730 00For
Fidelity386,3610 00For
AllianceBernstein167,2000 00For
Voya146,0630 00For
Renaissance120,1660 00For
Vanguard68,5130 00For
Rhumbline60,454582 00For
Goldman Sachs42,3390 00For

Institutional-manager reports, all 78 managers: 42,689,697 for, 10,221,670 against, 1,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

9. Ratification of appointment of independent registered public accounting firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 89,685,078AGAINST: 6,077,689
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

ATARA BIOTHERAPEUTICS INC.’s own tally for this item (“3. Ratification of appointment of independent registered public accounting firm”): 89,685,078 for, 6,077,689 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 16,185,137 for.

FOR
FOR: 16,185,137
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at ATARA BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,311,7720 00For
T. Rowe Price4,108,7590 00For
BlackRock2,876,8860 00For
Fidelity1,947,1000 00For
JPMorgan966,0000 00For
Charles Schwab762,0500 00For
Equitable400,9630 00For
John Hancock178,8630 00For
Lincoln Financial169,9910 00For
Voya146,0630 00For
AIG/SunAmerica47,7310 00For
Brighthouse38,0630 00For
Bridge Builder Trust37,5830 00For
Pacific Life36,1260 00For
Nationwide31,6000 00For
Principal Exchange-Traded Funds29,0620 00For
SEI20,6000 00For
State Street20,1070 00For
ProShares15,7240 00For
DWS13,0010 00For
Principal9,7260 00For
Calvert6,7820 00For
Morgan Stanley3,2640 00For
PENN SERIES FUNDS INC2,9280 00For
Guggenheim2,3720 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

Largest ATARA BIOTHERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 120,416,138 shares outstanding at the time of that meeting.

Fund voting reports: top ATARA BIOTHERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 3.58%
2T. Rowe Price 3.41%
3BlackRock 2.39%
4Fidelity 1.62%
5JPMorgan 0.80%
6Charles Schwab 0.63%
7Equitable 0.33%
8John Hancock 0.15%
9Lincoln Financial 0.14%
10Voya 0.12%
Institutional-manager reports: top ATARA BIOTHERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2023-2024
#Asset manager % of shares outstanding
1EcoR1 Capital, LLC 8.44%
2Redmile Group, LLC 7.69%
3T. Rowe Price 4.09%
4Citadel 3.86%
5Boxer Capital, LLC 3.45%
6BlackRock 2.16%
7Vestal Point Capital, LP 1.97%
8Woodline Partners LP 1.80%
9State Street 1.67%
10GEODE CAPITAL MANAGEMENT, LLC 1.43%

Reported ATARA BIOTHERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ATARA BIOTHERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
Panacea Innovation Limited 1.36% 13D
Adiumentum Capital Fund I LP 1.14% 13D
Redmile Group, LLC 0.59% 13D
Panacea Venture Healthcare Fund II, L.P. 0.46% 13G
Vanguard Group 0.17% 13F
BlackRock 0.06% 13F
Morgan Stanley 0.03% 13F
FMR (Fidelity) 0.01% 13F
JPMorgan Chase <0.01% 13F
Citadel Advisors LLC <0.01% 13G

Percentages above are of 120,416,138 shares outstanding, as reported by ATARA BIOTHERAPEUTICS INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATARA BIOTHERAPEUTICS INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

ATARA BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).

Cite this page

proxyvotesnow.com, “ATARA BIOTHERAPEUTICS (ATRA) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/atara-biotherapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.